Table 1.
The baseline features of the training and validation cohorts.
| Characteristic | Number of patients (%) | P-value | |
|---|---|---|---|
| Training cohort (n = 402) |
Validation cohort (n = 264) |
||
| Gender | |||
| Male | 325 (80.85%) | 220 (83.33%) | 0.415 |
| Female | 77 (19.15%) | 44 (16.67%) | |
| Age (years old) | |||
| < 60 | 215 (53.48%) | 143 (54.17%) | 0.862 |
| ≥ 60 | 187 (46.52%) | 121 (45.83%) | |
| Smoking status | |||
| No | 207 (51.49%) | 135 (51.14%) | 0.928 |
| Yes | 195 (48.51%) | 129 (48.86%) | |
| Drinking status | |||
| No | 290 (72.14%) | 183 (69.32%) | 0.432 |
| Yes | 112 (27.86%) | 81 (30.68%) | |
| Tumor location | |||
| Mouth | 163 (40.55%) | 112 (42.42%) | 0.94 |
| Pharynx | 71 (17.66%) | 47 (17.8%) | |
| Larynx | 130 (32.34%) | 83 (31.44%) | |
| Hypopharynx | 38 (9.45%) | 22 (8.33%) | |
| T stage | |||
| T1 | 93 (23.13%) | 59 (22.35%) | 0.908 |
| T2 | 147 (36.57%) | 97 (36.74%) | |
| T3 | 71 (17.66%) | 52 (19.7%) | |
| T4 | 91 (22.64%) | 56 (21.21%) | |
| N stage | |||
| N0 | 200 (49.75%) | 121 (45.83%) | 0.709 |
| N1 | 63 (15.67%) | 44 (16.67%) | |
| N2 | 126 (31.35%) | 92 (34.85%) | |
| N3 | 13 (3.23%) | 7 (2.65%) | |
| M stage | |||
| M0 | 381 (94.78%) | 246 (93.18%) | 0.391 |
| M1 | 21 (5.22%) | 18 (6.82%) | |
All continuous variables were changed to categorical variables.
Pearson χ2 test was used to compute the P-value.